A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
Study Details
Study Description
Brief Summary
Minimal risk research study:
-
Comparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus;
-
Quantifying the development and trajectory of the disease through clinic visits and blood values.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This work will serve both the Everett Clinic and broader UnitedHealth Group patient populations as well as advance the public health emergency response to the community spread of SARS-CoV-2 virus, especially as the number of cases and deaths continues to rise in many geographies. A recent study conducted at The Everett Clinic showed that foam nasal swabs were able to detect SARS-CoV-2 virus at comparable levels to nasopharyngeal (NP) swabs. We now look to build off this work by comparing polyester foam swabs, which are more readily available and mass producible, to foam nasal swabs, in their sensitivity for detecting SARS-CoV-2 virus. We also plan to assess the viability of dry swabbing, where the swab is stored without saline or viral transport media (VTM) at room temperature for four days, to calculate the degradation of the viral sample.
Finally, we will collect up to 50 mL/visit of blood longitudinally from patients who have previously tested positive for SARS-CoV-2 at visit one, two, and four weeks following their initial COVID-10 diagnosis.The medical professional drawing the blood will determine if the patient is at an increased risk from a blood draw due to underlying conditions such as anemia. In these cases, the amount of blood drawn will be left to the discretion of the medical professional but shall not surpass 10 mL per visit.These longitudinal blood samples will help us gain a better understanding of the trajectory of COVID-19 (in terms of both clinical symptomology and viral load) and antibody development. At each visit, nasal swabs and blood samples will be collected, and the blood samples will be stored in a repository for future research.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Odd numbered birth year The collection of patient samples will be different as defined by odd/even birth year. Patients born in an odd numbered year will first have their left nostril swabbed by the foam swab followed by their right nostril being swabbed by the two polyester swabs. |
Diagnostic Test: Odd/Even birth year intervention groups
The nostril used and order of testing will be different in each arm.
|
| Even numbered birth year The collection of patient samples will be different as defined by odd/even birth year. Patients born in an even numbered year will first have their left nostril swabbed by the two polyester swabs followed by their right nostril being swabbed by a foam swab. |
Diagnostic Test: Odd/Even birth year intervention groups
The nostril used and order of testing will be different in each arm.
|
Outcome Measures
Primary Outcome Measures
- Detection of SARS-CoV-2 virus [42 days]
Measure the agreement between the detection of SARS-CoV-2 virus using a foam nasal swab tested directly after collection, a polyester nasal swab tested directly after testing, and a polyester nasal swab stored at room temperature for four days without saline or VTM before being tested.
Secondary Outcome Measures
- Trajectory of COVID-19 and antibody development [2 months]
Longitudinal blood samples from SARS-CoV-2 patients to gain a better understanding of the trajectory of COVID-19 and antibody development
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Existing patient of the Everett Clinic (i.e., has previously sought care)
-
Tested positive for SARS-CoV-2 virus (confirmed by RT-PCR) prior to time of enrollment
Exclusion Criteria:
-
Not able to demonstrate understanding of the study
-
Not able to safely travel to the clinic without endangering themselves or risking exposing others to SARS-CoV-2
-
Medical history evidencing any of the following
-
Active nosebleed in the past 24 hours
-
Nasal surgery in the past two weeks
-
Chemotherapy treatment with low platelet and low white blood cell counts
-
Acute facial trauma
-
Advanced COVID-19 state that would preclude safe and feasible sample collection
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Everett Clinic | Seattle | Washington | United States | 98133 |
Sponsors and Collaborators
- UnitedHealth Group
- PATH
- Mayo Clinic
- Bill and Melinda Gates Foundation
Investigators
- Principal Investigator: Ethan Berke, UnitedHealth Group Research & Development
- Principal Investigator: Yuan Tu, OptumCare, Everett Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
- Coronavirus Disease 2019 (COVID-19) in the US. Centers for Disease Control and Prevention, accessed March 24, 2020. https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html
- Frosch, Dan, et al. "Coronavirus Testing Chaos Across America". Wall Street Journal, March 19, 2020
- Padilla, Mariel. " 'It feels like a war zone': Doctors and Nurses Plead for Masks on Social Media". New York Times, March 19, 2020
- 20-002